Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index; 15 of the 47 sources its claims cite were checked for support.

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Open access

Abstract

Background: Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synaptic dysfunction is an early feature in bvFTD and identification of specific biomarkers might improve its diagnostic accuracy. Our goal was to understand the differential diagnostic potential of cerebrospinal fluid (CSF) synaptic biomarkers in bvFTD versus PPD and their specificity towards bvFTD compared with Alzheimer’s disease (AD) and controls. Additionally, we explored the association of CSF synaptic biomarkers with social cognition, cognitive performance, and disease severity in these clinical groups. Methods: Participants with probable bvFTD (n = 57), PPD (n = 71), AD (n = 60), and cognitively normal controls (n = 39) with available CSF, cognitive tests, and disease severity as frontotemporal lobar degeneration-modified clinical dementia rating scale (FTLD-CDR) were included. In a subset of bvFTD and PPD cases, Ekman 60 faces test scores for social cognition were available. CSF synaptosomal-associated protein 25 (SNAP25), neurogranin (Ng), neuronal pentraxin 2 (NPTX2), and glutamate receptor 4 (GluR4) were measured, along with neurofilament light (NfL), and compared between groups using analysis of covariance (ANCOVA) and logistic regression. Diagnostic accuracy was assessed using ROC analyses, and biomarker panels were selected using Wald’s backward selection. Correlations with cognitive measures were performed using Pearson’s partial correlation analysis. Results: NPTX2 concentrations were lower in the bvFTD group compared with PPD (p < 0.001) and controls (p = 0.003) but not compared with AD. Concentrations of SNAP25 (p < 0.001) and Ng (p < 0.001) were elevated in patients with AD versus those with bvFTD and controls. The modeled panel for differential diagnosis of bvFTD versus PPD consisted of NfL and NPTX2 (AUC = 0.96, CI: 0.93–0.99, p < 0.001). In bvFTD versus AD, the modeled panel consisted of NfL, SNAP25, Ng, and GluR4 (AUC = 0.86, CI: 0.79–0.92, p < 0.001). In bvFTD, lower NPTX2 (Pearson’s r = 0.29, p = 0.036) and GluR4 (Pearson’s r = 0.34, p = 0.014) concentrations were weakly associated with worse performance of total cognitive score. Lower GluR4 concentrations were also associated with worse MMSE scores (Pearson’s r = 0.41, p = 0.002) as well as with worse executive functioning (Pearson’s r = 0.36, p = 0.011) in bvFTD. There were no associations between synaptic markers and social cognition or disease severity in bvFTD. Conclusion: Our findings of involvement of NTPX2 in bvFTD but not PPD contribute towards better understanding of bvFTD disease pathology.

Overview

CoChat Summary

TL;DR

In a memory-clinic cohort, CSF NPTX2 was lower in bvFTD than in PPD and controls, while SNAP25 and Ng were elevated in AD; biomarker panels including NfL discriminated bvFTD from PPD (AUC 0.96) and bvFTD from AD (AUC 0.86). Synaptic biomarkers showed limited added diagnostic value and weak or absent associations with social cognition and disease severity.

Key findings

  • CSF NPTX2 concentrations were lower in bvFTD than PPD (p < 0.001) and controls (p = 0.003 in the abstract; p = 0.005 in the results), but not significantly lower than in AD.
  • SNAP25 and Ng were elevated in AD compared with bvFTD, PPD, and controls (p < 0.001 for all); NfL was higher in bvFTD than AD, PPD, and controls (p < 0.001 for all).
  • The selected panel for bvFTD vs PPD was NfL + NPTX2 (AUC = 0.96, CI 0.93–0.99, p < 0.001); for bvFTD vs AD it was NfL + SNAP25 + Ng + GluR4 (AUC = 0.86, CI 0.79–0.92, p < 0.001).
  • In bvFTD, lower NPTX2 (r = 0.29, p = 0.036) and GluR4 (r = 0.34, p = 0.014) were weakly associated with worse total cognitive score; no synaptic marker correlated with social cognition or FTLD-CDR disease severity.

Methods

  • Participants with probable bvFTD (n = 57), PPD (n = 71), AD (n = 60), and cognitively normal controls (n = 39) from the Alzheimer Center Amsterdam (2003–2021) had CSF, cognitive tests, and disease severity measures; Ekman 60 faces test scores were available for a subset (bvFTD n = 13; PPD n = 9).
  • CSF SNAP25, Ng, NPTX2, GluR4, and NfL were measured; group comparisons used ANCOVA adjusted for age, sex, and psychotropic medication use, with logistic regression, ROC analyses, Wald’s backward selection for panels, and Pearson’s partial correlations controlling for age.

Limitations

  • Stated: odds ratios for synaptic biomarkers were modest, and the clinical relevance of NPTX2 requires evaluation in larger cohorts; the PPD sample was heterogeneous, so disease-specific synaptic concentrations in PPD could not be assessed; sample sizes for cognitive test scores were limited, including social cognition, FTLD-CDR, and visuospatial functioning.
  • Evident from the text: the bvFTD cohort had only mild-to-moderate disease severity (FTLD-CDR ≤ 16), limiting assessment across severity stages; GluR4 had higher assay variability (25% CV) than the other immunoassays.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13195-024-01409-8

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Concentrations of candidate CSF biomarkers across the diagnostic groups. Analysis of covariance (ANCOVA) models corrected for age, sex, and psychotropic medication use with post hoc pairwise comparisons were used to determine the log10 transformed biomarker differences between the clinical groups, with Bonferroni’s multiple comparison correction. A SNAP25. B Ng. C NPTX2. D GluR4. E NfL. SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4; NfL, neurofilament light. bvFTD, behavioral frontotemporal dementia; PPD, primary psychiatric disorders; AD, Alzheimer’s disease. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 1 Concentrations of candidate CSF biomarkers across the diagnostic groups. Analysis of covariance (ANCOVA) models corrected for age, sex, and psychotropic medication use with post hoc pairwise comparisons were used to determine the log10 transformed biomarker differences between the clinical groups, with Bonferroni’s multiple comparison correction. A SNAP25. B Ng. C NPTX2. D GluR4. E NfL. SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4; NfL, neurofilament light. bvFTD, behavioral frontotemporal dementia; PPD, primary psychiatric disorders; AD, Alzheimer’s disease. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 2 ROC curves showing the differentiation accuracy between the diagnostic groups of biomarkers in CSF. A bvFTD versus PPD, Panel-NfL, NPTX2. B bvFTD versus AD, Panel-NfL, SNAP25, Ng, GluR4. AUCs are shown for biomarkers alone. bvFTD, behavioral variant frontotemporal dementia, PPD, primary psychiatric disorders; AD, Alzheimer’s disease; AUC, area under curve; ROC, receiver operating characteristics; NfL, neurofilament; SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4
Fig. 2 ROC curves showing the differentiation accuracy between the diagnostic groups of biomarkers in CSF. A bvFTD versus PPD, Panel-NfL, NPTX2. B bvFTD versus AD, Panel-NfL, SNAP25, Ng, GluR4. AUCs are shown for biomarkers alone. bvFTD, behavioral variant frontotemporal dementia, PPD, primary psychiatric disorders; AD, Alzheimer’s disease; AUC, area under curve; ROC, receiver operating characteristics; NfL, neurofilament; SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4CC BY · PubMed Central
Fig. 3 Correlation matrix of the fluid biomarkers to cognitive test performance and social test scores in patients with bvFTD, PPD, AD, and controls. The associations are shown as Pearson’s partial correlations, controlling for age. bvFTD, behavioral variant frontotemporal dementia; PPD, primary psychiatric disorders; AD, Alzheimer’s disease; NfL, neurofilament light; SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4; MMSE, mini-mental state examination; FTLD-CDR, frontotemporal lobe dementia-cognitive dementia rating. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 Correlation matrix of the fluid biomarkers to cognitive test performance and social test scores in patients with bvFTD, PPD, AD, and controls. The associations are shown as Pearson’s partial correlations, controlling for age. bvFTD, behavioral variant frontotemporal dementia; PPD, primary psychiatric disorders; AD, Alzheimer’s disease; NfL, neurofilament light; SNAP25, synaptosomal-associated protein 25; Ng, neurogranin; NPTX2, neuronal pentraxin 2; GluR4, glutamate receptor 4; MMSE, mini-mental state examination; FTLD-CDR, frontotemporal lobe dementia-cognitive dementia rating. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 1 Not valid · 14 Not checked · 75 Own results and interpretations

55 more claims · 2 with their cited sources checked

Create a free account to see all 98 claims and to verify the 32 references still open.

See all claims — free account
  • Probably not a substantial claim. 30
  • It may state two separate claims as one. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. Alzheimers Dis. 2018;62(3):1091–1111. https://doi.org/10.3233/JAD-170850. · DOI · Paper page

Cited by

See all 12

Metadata

Authors
Das, S., van Engelen, M.-P. E., Goossens, J., Jacobs, D., Bongers, B., Fieldhouse, J. L. P., Pijnenburg, Y. A. L., Teunissen, C. E., Vanmechelen, E., & Verberk, I. M. W.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Amsterdam Neuroscience (NL)
  • ADx NeuroSciences (BE)
Corresponding author
Verberk, Inge M. W.
Venue
Alzheimer's Research & Therapy
Published
2024-02-14
Volume
16
Issue
1
Pages
34-34
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4391821162
Cited by
12
References
55
Citations by year
2026: 1 · 2025: 8 · 2024: 3
FWCI
3.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
Funders
  • European Union's Horizon 2020 research and innovation Marie Curie program ‘MIRIADE’ (860197)
  • Stichting Alzheimer Nederland
  • Stichting Dioraphte
  • ZonMW-funded PRODIA project (#ZonMW 733050206)
  • Stichting VUmc
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
behavioral variant frontotemporal dementia, cerebrospinal fluid biomarkers, synaptic dysfunction, differential diagnosis, primary psychiatric disorders, Alzheimer's disease, NPTX2, SNAP-25, neurogranin, neurofilament light chain, social cognition, biomarker panel, disease severity, cognitive performance, frontotemporal lobar degeneration
MeSH terms
Alzheimer Disease, Humans, Neuropsychological Tests, ROC Curve, Biomarkers, Frontotemporal Lobar Degeneration, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-024-01409-8
The paper
Das, S., van Engelen, M.-P. E., Goossens, J., Jacobs, D., Bongers, B., Fieldhouse, J. L. P., Pijnenburg, Y. A. L., Teunissen, C. E., Vanmechelen, E., & Verberk, I. M. W. (2024). The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-024-01409-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.